MMV 23rd call for proposals -2026

MMV welcomes proposals in the following areas:

1. Compounds having activity against all Plasmodium spp. blood stages in vitro  (TCP1-TPP1) for use in treatment or chemoprevention (TCP1-TPP2).
2. Compounds addressing the key priorities of the malaria elimination/ eradication agenda (TCP3).
3. Innovative biology: large molecules, as long-acting injectables addressing chemoprevention.

Funding: no fixed limit 

Duration: 1 year

Research Authority due date: 19.2.26

LOI (required) due date: 27.2.26

Full proposal due date: upon request